辰欣药业：股东韩延振计划减持不超过约1358万股

Group 1 - The core business of Chenxin Pharmaceutical is primarily in the pharmaceutical manufacturing sector, accounting for 99.75% of its total revenue for the year 2024 [1] - Other business activities contribute a minimal 0.25% to the overall revenue of Chenxin Pharmaceutical [1] Group 2 - As of August 5, Chenxin Pharmaceutical announced that major shareholder Han Yanzhen holds approximately 31.98 million shares, representing 7.06% of the total share capital [3] - Han Yanzhen plans to reduce his holdings by up to 4.53 million shares through centralized bidding, not exceeding 1% of the total share capital, and by up to 9.06 million shares through block trading, not exceeding 2% of the total share capital, totaling a maximum reduction of approximately 13.58 million shares or 3% of the total share capital [3] - The reduction plan allows for adjustments in case of corporate actions such as dividend distributions or stock splits during the implementation period [3]